GeneDx

GeneDx (formerly Sema4) GeneDx is an AI-powered genomic and clinical data intelligence platform. It combines longitudinal patient data, AI models, and genomics with other clinical data to derive insights. GeneDx's platform enables treatment matching, drug target identification, and diagnostic testing. The company provides diagnostic solutions for reproductive health, women's health, hereditary cancer, oncology, and more. GeneDx has built one of the largest integrated health data platforms, with over 12 million de-identified clinical records and 500,000 genomic profiles.

GeneDx processes over 46+ petabytes of data monthly. This powers genomic-based, proactive disease diagnosis and management for healthcare providers. The company operates on a B2B2C model, getting reimbursed by insurance providers. GeneDx also partners with biopharmas to support drug development, real-world evidence studies, and clinical trial recruitment.

GeneDx, formerly part of Opko Health, was acquired by Sema4 in April 2022 for USD 623 million. Since the acquisition, Sema4 has focused on growing the GeneDx business and branding.

Key customers and partnerships

In August 2023, the company partnered with PacBio and the University of Washington to enhance pediatric genetic diagnosis, and also partnered with Prognos Health to expand customer access. 

Funding and financials 

In January 2023, the company changed its name to GeneDx Holdings Corp from Sema4 and traded under the ticker symbol “WGS'' on the Nasdaq Exchange. Also in January 2023, the company raised USD 150 million via an underwritten public offering consisting of 428.6 million common shares priced at USD 0.35 per share. The new funds were allocated towards general corporate expenses including working capital, repayment of debts, and strategic investments.

For 2022 the company reported a net loss of USD 549 million (up 123.7% YoY) while revenue was USD 227.3 million (up 10.8% YoY). For 2023, the company expects its full-year revenue guidance to be at USD 205 million–220 million, implying a decrease of 6%-13%.